Research progress on the role of lipoxygenase and its inhibitors in prostate cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.The lipoxygenase (LOX) pathway impacts prostate cancer (PCa) progression. LOX inhibitors offer a potential therapeutic strategy by targeting enzymes like 5-LOX, 12-LOX, and 15-LOX-2 involved in PCa.
Area Of Science
- Oncology
- Biochemistry
- Molecular Biology
Background
- Prostate cancer (PCa) is a prevalent malignancy in aging men.
- The lipoxygenase (LOX) pathway is implicated in PCa's occurrence, development, invasion, and metastasis.
- Specific LOX enzymes, including 5-LOX, 12-LOX, and 15-LOX-2, exhibit distinct roles in PCa progression.
Purpose Of The Study
- To review the mechanistic roles of the LOX pathway in prostate cancer.
- To explore the potential of LOX inhibitors for PCa prevention and treatment.
- To provide a reference for future research on LOX-targeted therapies in PCa.
Main Methods
- Literature review of studies on the lipoxygenase pathway in prostate cancer.
- Analysis of the roles of 5-LOX, 12-LOX, and 15-LOX-2 in PCa.
- Examination of the efficacy of LOX inhibitors in preclinical and clinical settings.
Main Results
- 5-LOX and 12-LOX promote PCa occurrence, development, invasion, and metastasis.
- 15-LOX-2 demonstrates an inhibitory effect on PCa.
- LOX inhibitors effectively suppress the metabolic activity of LOX enzymes.
Conclusions
- The LOX pathway represents a significant therapeutic target for prostate cancer.
- Targeting specific LOX enzymes with inhibitors may offer novel strategies for PCa management.
- Further research into LOX inhibitors is warranted for effective PCa prevention and treatment.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Peroxisomes are specialized organelles present in fungi, plant, and animal cells. It can vary in number, size, morphology, and activity depending on the type of tissue and the nutritional state of the cell. For example, cells with active lipid metabolism, such as adipocytes, neurons, and hepatocytes, have more peroxisomes than other cells in the body. Besides their primary role in breaking down complex organic molecules, peroxisomes can also synthesize specific macromolecules and participate in...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...